select a format

Single User License
USD 2000 INR 130040
Site License
USD 4000 INR 260080
Corporate User License
USD 6000 INR 390120

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline Review, H1 2017

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline Review, H1 2017


  • Products Id :- GMDHC9060IDB
  • |
  • Pages: 62
  • |
  • March 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy-Pipeline Review, H1 2017, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline landscape.

Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as chronic relapsing polyneuropathy is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disease is caused by damage to the myelin sheath of the peripheral nerves. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling and numbness of hands and feet.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 1, 1 and 1 respectively.

Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Overview

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Companies Involved in Therapeutics Development

CSL Ltd

GeNeuro SA

MedDay SA

Mitsubishi Tanabe Pharma Corp

Octapharma AG

Pfizer Inc

Shire Plc

Teijin Pharma Ltd

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Drug Profiles

biotin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fingolimod hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GL-2045-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNbAC-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hyaluronidase (human) (recombinant) + immune globulin (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Dormant Projects

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Product Development Milestones

Featured News & Press Releases

Mar 01, 2017: CSL Behring Announces Largest Ever CIDP Clinical Study Completed

Feb 14, 2017: FDA Accepts CSL Behring's Biologics License Application Supplement for Using Privigen to Treat Chronic Inflammatory Demyelinating Polyneuropathy, a Rare Neurological Condition

Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder

Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy

Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen

Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy

May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline by CSL Ltd, H1 2017

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline by GeNeuro SA, H1 2017

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline by MedDay SA, H1 2017

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline by Octapharma AG, H1 2017

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline by Pfizer Inc, H1 2017

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline by Shire Plc, H1 2017

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline by Teijin Pharma Ltd, H1 2017

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

CSL Ltd, GeNeuro SA, MedDay SA, Mitsubishi Tanabe Pharma Corp, Octapharma AG, Pfizer Inc, Shire Plc, Teijin Pharma Ltd

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutic Products under Development, Key Players in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Overview, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com